Rheumatology News and Research

RSS

Rheumatology is a sub-specialty in internal medicine and pediatrics, devoted to the diagnosis and therapy of rheumatic diseases. Rheumatologists mainly deal with clinical problems involving joints, soft tissues and allied conditions of connective tissues.

Idera Pharmaceuticals announces net income of $3.9M for fourth-quarter 2009

Idera Pharmaceuticals, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2009.

10 Mar 2010

Childhood bad behaviour linked to chronic widespread pain in adult life

Bad behaviour in childhood is associated with long-term, chronic widespread pain in adult life, according to the findings of a study following nearly 20,000 people from birth in 1958 to the present day.

10 Mar 2010

Bioniche Pharma introduces Mefoxin in frozen premix bags

Bioniche Pharma, a leading developer and manufacturer of injectable pharmaceuticals, announced today the launch of Mefoxin® (cefoxitin injection) frozen premix bags. The launch marks the company's first product offering to be supplied in a frozen premix bag presentation. Mefoxin (cefoxitin injection) is manufactured by Baxter Healthcare Corporation using Baxter's proprietary GALAXY container technology.

9 Mar 2010

Study finds sizeable position for Actemra in rheumatoid arthritis treatment paradigm

Results from a study conducted by Majestic Research suggest that Bristol Myers Squibb's Orencia, Johnson & Johnson's Remicade, and Amgen's/Wyeth's Enbrel will forfeit share of the rheumatoid arthritis market to Roche's newly launched Actemra. Early switching data from Majestic’s proprietary panel of rheumatologists indicates that Orencia may be the biggest loser of all, as 54% of switches to Actemra thus far have been from Orencia.

9 Mar 2010

KAPIDEX to be marketed as DEXILANT in the U.S.

Takeda Pharmaceuticals North America, Inc. announced today that KAPIDEX™ (dexlansoprazole) will be marketed in the United States under the new product trade name DEXILANT™ (dexlansoprazole). The product is indicated for heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD), the healing of erosive esophagitis (EE) and the maintenance of healed EE.

5 Mar 2010

Data evaluating safety, efficacy of STELARA and REMICADE in patients with plaque psoriasis to be presented

Data evaluating the efficacy and safety of STELARA™ (ustekinumab) and REMICADE® (infliximab) in patients with plaque psoriasis who had an inadequate response to Enbrel® (etanercept) will be presented at the 68th Annual Meeting of the American Academy of Dermatology (AAD) in Miami, Fla., from March 5-9, 2010.

5 Mar 2010

FDA approves CSL Behring's Hizentra for PI

CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for HizentraTM, Immune Globulin Subcutaneous (Human), 20% Liquid, for treating patients diagnosed with primary immunodeficiency (PI). A once weekly immunoglobulin (Ig) replacement therapy, Hizentra provides effective protection against infection by maintaining a steady and normal level of immunoglobulin in the body.

4 Mar 2010

POZEN reports net loss of $6.9M for year ended December 31, 2009

POZEN Inc., today announced results for the fourth quarter and year ended December 31, 2009.

3 Mar 2010

Report provides comprehensive insight into how physicians classify and treat patients with gout

BioTrends Research Group, Inc. is pleased to announce the availability of its TreatmentTrends®: Gout and Hyperuricemia publication. The report is based on responses to online surveys completed by 120 Rheumatologists and 57 Primary Care Physicians in the US who are managing a high number of patients with gout.

3 Mar 2010

Individuals who naturally lack CCR5 receptor have resistant to HIV

UCLA AIDS Institute researchers successfully removed CCR5 - a cell receptor to which HIV-1 binds for infection but which the human body does not need - from human cells. Individuals who naturally lack the CCR5 receptor have been found to be essentially resistant to HIV.

26 Feb 2010

Increase in anti-Apo A-I, anti-HDL and anti-CRP may lead to atherosclerosis in SLE patients

A study by researchers in Australia and the United Kingdom suggests that autoantibodies to fat binding proteins significantly increase in systemic lupus erythematosus (SLE) patients with active disease. This increase in anti-apolipoprotein (anti-Apo A-I), anti-high-density lipoprotein (anti-HDL), and anti-C-reactive protein (anti-CRP) may contribute to the development of atherosclerosis in SLE patients, placing them at risk for cardiovascular disease (CVD).

25 Feb 2010

Prevalence of arthritis and AAL may be effect of obesity and physical inactivity, particularly in women

Researchers from the Toronto Western Research Institute noted a higher prevalence of arthritis and arthritis-attributable activity limitations (AAL) in the U.S. versus the Canadian population. The authors attribute the higher prevalence of arthritis and AAL to a greater level of obesity and physical inactivity in Americans, particularly women.

25 Feb 2010

SSRIs exhibit anti-inflammatory effects and may provide drug development opportunities for RA

A new study found that fluoxetine (Prozac-) and citalopram (Celexa-) treatment significantly inhibited disease progression of collagen-induced arthritis (CIA) in mice. Research led by Sandra Sacre, Ph.D. from the Brighton and Sussex Medical School (BSMS) in the UK studied the anti-arthritic potential of these drugs, known as selective serotonin reuptake inhibitors (SSRIs), most commonly used to treat depression.

25 Feb 2010

ACR REF Clinician Scholar Education Award for rheumatology health professionals

At the core of the American College of Rheumatology Research and Education Foundation's mission is to attract the best and brightest trainees into a career in rheumatology. To do this, the REF has an extensive portfolio of awards and grants that provide support during critical career stages.

22 Feb 2010

FDA accepts filing of Jazz Pharmaceuticals' NDA for sodium oxybate

Jazz Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has accepted for filing the New Drug Application (NDA) for JZP-6 (sodium oxybate) for the treatment of fibromyalgia.

19 Feb 2010

Incyte announces 2009 financial results and key fourth-quarter accomplishments

Incyte Corporation today reported fourth quarter and full year 2009 financial results, provided an update on key fourth quarter accomplishments and 2010 objectives, and announced its 2010 financial guidance.

18 Feb 2010

Hip and knee replacement surgery at specialized hospitals lead to better outcomes for patients

The more specialized a hospital is in orthopedic surgical care, the better the outcomes appear to be for patients undergoing hip and knee replacement surgery, University of Iowa researchers report in a new study of Medicare patients.

16 Feb 2010

Surgical outcomes for hip and knee replacement better at specialized hospitals

15 Feb 2010

HSS creates Quality Research Center for applying research methodologies to health-care quality issues

Patients with orthopedic and autoimmune conditions expect Hospital for Special Surgery --because of its leadership role--to deliver the highest quality care. To further accomplish this mission, HSS is announcing the creation of a Quality Research Center with an innovative structure for applying research methodologies to health-care quality issues.

15 Feb 2010

Siemens Healthcare renews strategic alliance with NextGen Healthcare Information Systems

Today, Siemens Healthcare announced it has renewed its strategic alliance with NextGen Healthcare Information Systems to deliver innovative ambulatory information technology (IT) solutions. More than 35 Siemens customers have already deployed NextGen Healthcare's ambulatory IT tools throughout their physician networks as a result of the relationship, formed to offer healthcare providers interoperable solutions that cross the care coordination gap between the acute and ambulatory environments.

12 Feb 2010

Rheumatology News and Research

Further Reading

Idera Pharmaceuticals announces net income of $3.9M for fourth-quarter 2009

Childhood bad behaviour linked to chronic widespread pain in adult life

Bioniche Pharma introduces Mefoxin in frozen premix bags

Study finds sizeable position for Actemra in rheumatoid arthritis treatment paradigm

KAPIDEX to be marketed as DEXILANT in the U.S.

Data evaluating safety, efficacy of STELARA and REMICADE in patients with plaque psoriasis to be presented

FDA approves CSL Behring's Hizentra for PI

POZEN reports net loss of $6.9M for year ended December 31, 2009

Report provides comprehensive insight into how physicians classify and treat patients with gout

Individuals who naturally lack CCR5 receptor have resistant to HIV

Increase in anti-Apo A-I, anti-HDL and anti-CRP may lead to atherosclerosis in SLE patients

Prevalence of arthritis and AAL may be effect of obesity and physical inactivity, particularly in women

SSRIs exhibit anti-inflammatory effects and may provide drug development opportunities for RA

ACR REF Clinician Scholar Education Award for rheumatology health professionals

FDA accepts filing of Jazz Pharmaceuticals' NDA for sodium oxybate

Incyte announces 2009 financial results and key fourth-quarter accomplishments

Hip and knee replacement surgery at specialized hospitals lead to better outcomes for patients

Surgical outcomes for hip and knee replacement better at specialized hospitals

HSS creates Quality Research Center for applying research methodologies to health-care quality issues

Siemens Healthcare renews strategic alliance with NextGen Healthcare Information Systems

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News